Percutaneous renal denervation: new treatment option for resistant hypertension and more?
- Authors: Sebastian Ewen, Christian Ukena, Michael Böhm, Felix Mahfoud
- Reference: Heart 2013;0:1–6.
- Published: 6 March 2013
- Link: Access abstract here
My comment by Sebastian Ewen
- is a new promising treatment method for resistant arterial hypertension.
- reduces blood pressure and increases blood pressure control rates.
- might positively influence other cardiovascular morbidities, characterized by increased sympathetic activity, including hyperinsulinemia, obstructive sleep apnea syndrome, left ventricular hypertrophy, and diastolic dysfunction.
The following criteria should be fulfilled before a patient is considered for renal denervation:
- SBP ≥160 mmHg (≥150 mmHg diabetes type 2)
- ≥3 antihypertensive drugs in adequate dosage and combination (incl. diuretic)
- Life-style modification
- Exclusion of secondary hypertension
- Exclusion of pseudo-resistance (ABPM)
- Preserved renal function (eGFR ≥45 ml/min/1,73 m2)
- Eligible renal arteries: no stenosis, no PTA/stenting
Clinical trials and registries with prolonged follow-up periods are required to assess the durability and safety of renal denervation over time.
Numerous new catheter systems and treatment modalities are in development.
To leave a comment, please create your free account here!